Taking the small bladder recurrence out of theatre

Design

preclinical in vivo study in 13 pigs followed by a prospective, open-label, single-arm first-in-human clinical investigation

Population

18 adults with recurrent Ta/T1 non-muscle-invasive bladder cancer, lesions ≤10 mm, under local anaesthesia via flexible cystoscopy

Primary outcome

proportion of histologically evaluable biopsies

Effect

134/145 biopsies (92%) evaluable, per-patient diagnostic yield 89%; no device-related adverse events or Clavien-Dindo complications; median pain 0.5/10; estimated per-procedure cost 73–89% lower than transurethral resection

Small recurrent non-muscle-invasive bladder cancer generates an enormous amount of theatre activity: a patient with frequent small recurrences returns for transurethral resection under anaesthesia repeatedly, each time for a lesion of a few millimetres. A first-in-human study tested an instrument designed to move that into the outpatient room, integrating local anaesthetic injection, diathermy biopsy, coagulation and automated tissue retrieval in one device used through a flexible cystoscope.

Preclinical work in 13 pigs and 550 biopsies established immediate haemostasis, preserved tissue architecture and a perforation threshold of 7 to 11 sequential biopsies at the same site. The clinical study was a prospective, open-label, single-arm investigation in 18 adults with recurrent Ta or T1 disease and lesions of 10 mm or less. The primary endpoint was met: 134 of 145 biopsies (92%) were histologically evaluable, with a per-patient diagnostic yield of 89%. No device-related adverse events or Clavien-Dindo complications occurred, every procedure was completed under local anaesthesia without conversion, and the median pain score was 0.5 out of 10. Estimated per-procedure cost was 73 to 89% lower than transurethral resection.

Eighteen patients is a feasibility study and nothing more — there is no comparison arm, no oncological follow-up, and no evidence about recurrence or progression after outpatient management rather than formal resection. But the resource argument is exactly the kind that matters in a high-volume Indian practice, where theatre access rather than surgical skill is often the constraint on how promptly a recurrence is dealt with. This is worth following.

• This is feasibility evidence — do not change surveillance or treatment pathways on it.
• Note the lesion size limit: 10 mm or less, Ta or T1 recurrence, in a selected group.
• There is no oncological follow-up here; recurrence and progression after outpatient management are unknown.
• The cost estimate is modelled per procedure, not a measured health-system saving.
• Watch for a comparative trial against standard transurethral resection before considering adoption.

Why it matters

If small recurrences can be handled in a clinic room, the constraint on how promptly they are treated stops being theatre access.

Don't overread it

A single-arm feasibility study in 18 patients — it says the device works, not that outpatient management is oncologically equivalent.

The statistics, in plain English

A 92% evaluable-biopsy rate sounds convincing, but the denominator is 145 biopsies from 18 selected patients at one centre with the developers involved, which is the least generalisable setting there is. With no control arm, the comparison against transurethral resection is implicit rather than measured, and the 73–89% cost reduction is an estimate built on assumptions about resource use rather than an observed difference. A median pain score of 0.5 out of 10 is genuinely low, but pain is unblinded and self-reported in a study everyone knew was testing a new device.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.